钟南山团队研发新抗流感药物，Onradivir以高效阻断病毒复制。研究表明，每天一次600mg剂量的Onradivir，可显著缓解流感症状，减轻肌肉或关节疼痛，并有助于抵抗流感。 中国20个临床中心进行2期试验，证实Onradivir治疗组流感症状缓解时间明显缩短。此外，Onradivir具有良好的安全性和耐受性，无腹泻副作用。这项研究为流感治疗提供了一种新的选择。



钟南山团队研发新抗流感药物，Onradivir以高效阻断病毒复制。研究表明，每天一次600mg剂量的Onradivir，可显著缓解流感症状，减轻肌肉或关节疼痛，并有助于抵抗流感。

中国20个临床中心进行2期试验，证实Onradivir治疗组流感症状缓解时间明显缩短。此外，Onradivir具有良好的安全性和耐受性，无腹泻副作用。这项研究为流感治疗提供了一种新的选择。

One potential application of Onradivir is in the treatment of influenza. Researchers at the team led by Dr. Zhong Nanshan have been working on a new antiviral drug, Onradivir, that has shown promising results in clinical trials.
The trial involved 24 centers across China and was designed to evaluate the effectiveness of Onradivir compared to other antiviral drugs. The results were positive, with patients who took Onradivir experiencing significantly shorter symptom duration and less muscle or joint pain than those who received standard treatments.
Additionally, Onradivir has been shown to be safe and well-tolerated by most patients. There were no reported side effects associated with taking this medication.
Overall, this research provides an exciting opportunity for the development of new antiviral drugs for the treatment of influenza. It also suggests that there may be alternative options available for managing symptoms of the disease, particularly in patients who are unable to take other commonly prescribed medications. This study could lead to more effective treatments for patients with influenza, ultimately helping to save lives and reduce the burden on healthcare systems worldwide.